Evidence map›Paper›PMID 41501809›Full record

ReviewCell communication and signaling : CCS2026

Winners take it all: turning cell competition into a therapeutic ally.

Tereza Fantová, Maxima Warmuzová, Sandra Charvátová, Kateřina Stošková, Tomáš Jelínek, Michal Šimíček, Roman Hájek, Juli R Bagó

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tereza Fantová *Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Maxima Warmuzová *Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Sandra CharvátováDepartment of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Kateřina StoškováDepartment of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Tomáš JelínekDepartment of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Michal ŠimíčekDepartment of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Roman HájekDepartment of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Juli R BagóDepartment of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. julio.rodriguez@osu.cz.

Funding

Czech Health Research Council NU23-03-00374EHA Physician Scientist Research Grant RG-202409-06772European Union project LERCO No. CZ.10.03.01/00/22_003/0000003Institutional support from the Ministry of Health of the Czech Republic MH CZ-DRO- FNOs/2024, 1/OR-FNO/2025Programme Johannes Amos Comenius under the Ministry of Education, Youth and Sports of the Czech Republic Salvage CZ.02.01.01/00/22_008/0004644The student's grant system of the University of Ostrava SGS20/LF/2025
6 · The paper itself

Abstract

Recent discoveries in the field of cell competition have brought this phenomenon into the spotlight due to its potential to inspire novel therapeutic approaches for previously incurable diseases.Cell competition, a process observed across multicellular organisms, acts as a natural quality control mechanism in which unfit, abnormal, or malignant cells are actively eliminated by neighboring, healthy-fit cells. However, the mechanisms and outcomes of cell competition are highly context-dependent, influenced by the environment, developmental stage, and specific tissue involved. Emerging research also highlights a darker aspect where cancer cells can hijack cell competition to their advantage, promoting tumor growth and progression. A deeper understanding of cell competition opens up a wide range of therapeutic possibilities for diseases that currently lack effective treatments. Given its specificity and context-dependence, we categorize these therapeutic opportunities based on the physiological settings in which cell competition occurs.

Indexed as

Cell CompetitionNeoplasmsAnimalsHumansAgingApoptosis.CancerCell competitionEDACLoser cellsPluripotent stem cellsRegenerative medicineSenescenceSuper-CompetitionTherapyWinner cells

Identifiers

PMID41501809
PMCPMC12870730

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.